Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
M Komori, YC Lin, I Cortese, A Blake… - Annals of clinical …, 2016 - Wiley Online Library
Objective Inaccessibility of the inflammation compartmentalized to the central nervous
system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in …
system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in …
[HTML][HTML] Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
M Komori, YC Lin, I Cortese, A Blake… - Annals of Clinical and …, 2016 - ncbi.nlm.nih.gov
Objective Inaccessibility of the inflammation compartmentalized to the central nervous
system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in …
system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in …
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.
M Komori, YC Lin, I Cortese, A Blake… - Annals of Clinical & …, 2016 - search.ebscohost.com
Objective Inaccessibility of the inflammation compartmentalized to the central nervous
system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in …
system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in …
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.
M Komori, YC Lin, I Cortese, A Blake… - Annals of Clinical and …, 2016 - europepmc.org
Objective Inaccessibility of the inflammation compartmentalized to the central nervous
system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in …
system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in …
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
M Komori, YC Lin, I Cortese, A Blake… - Annals of clinical …, 2016 - pubmed.ncbi.nlm.nih.gov
Objective Inaccessibility of the inflammation compartmentalized to the central nervous
system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in …
system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in …
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
M Komori, YC Lin, I Cortese, A Blake… - Annals of Clinical …, 2016 - search.proquest.com
Objective Inaccessibility of the inflammation compartmentalized to the central nervous
system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in …
system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in …
[PDF][PDF] Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
M Komori, YC Lin, I Cortese, A Blake, J Ohayon… - Neurology, 2016 - cyberleninka.org
Objective: Inaccessibility of the inflammation compartmentalized to the central nervous
system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in …
system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in …
[PDF][PDF] Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
M Komori, YC Lin, I Cortese, A Blake, J Ohayon… - Neurology, 2016 - researchgate.net
Objective: Inaccessibility of the inflammation compartmentalized to the central nervous
system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in …
system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in …